Paratek Pharmaceuticals (PRTK) 10-K2011 FY Annual report

Filed: 30 Mar 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandon, abbreviated, abundance, academic, altogether, ANDA, anecdotal, Australia, body, bothersome, calendar, cavity, central, certainty, circumstance, clear, cumulative, deep, dictate, disclaim, dispersed, Distinguishing, episodic, Factor, fault, flexibility, float, formation, fortieth, GAAP, grow, heart, interim, irregular, Kessler, marketplace, men, molecule, monetizing, monthly, ofBoth, partly, passage, penetration, personal, promising, prone, pronouncement, proper, psychiatrist, QT, quantify, Recognitionon, refrain, reset, retrospective, rhythm, Ronald, sentence, smooth, strength, stronger, Teva, thirteen, Tmax, turn, undergoing, unqualified, visibility, women, yearly

Removed: Abuse, Actelion, affectIntermezzo, age, agree, alert, analog, analyzed, Anderson, andIntermezzo, applicability, approvable, asIntermezzo, awakened, awoke, backup, bar, baseline, batch, beforeIntermezzo, Bimucoral, binary, blocked, blood, byIntermezzo, category, cognitive, commercializeIntermezzo, comparison, confirmed, consistently, constituting, contemplated, convert, coverIntermezzo, crossover, curve, deem, demonstrating, description, digit, DSST, Eli, enabled, enabling, encompassIntermezzo, endpoint, enhanced, examine, facilitate, feeling, figure, forIntermezzo, function, givenIntermezzo, hangover, home, ifintermezzo, illustrated, impaired, improved, includingIntermezzo, induce, inducing, inIntermezzo, innovation, Intermezzo®utilizesBimucoral, keyIntermezzo, largely, Latency, launchIntermezzo, left, likelihood, Lilly, manufacturedIntermezzo, marketIntermezzo, measurable, mgIntermezzo, mgIntermezzo®returned, mgIntermezzo®tablet, Mikart, minimize, minute, mouth, mutual, mutually, neitherIntermezzo, noncurrent, notably, objectively, observation, obtainIntermezzo, ofIntermezzo, ofIntermezzo®on, outpatient, parallel, peak, permit, Persistent, pharmacodynamic, pharmacokinetic, presence, prevalence, protectIntermezzo, prototype, quickly, randomized, recognizing, reconsider, reliable, reliably, renew, renewable, renewed, returned, saliva, scale, Schering, sedation, sellIntermezzo, showed, sleepy, soda, staffed, statistically, sublicense, submitting, Substitution, successive, suggesting, superior, supplementary, swallowed, takeIntermezzo®in, takingIntermezzo, thatIntermezzo, theIntemezzo, theintermezzo, toIntermezzo, toIntermezzo®and, tongue, trazadone, unapproved, undelivered, unexpired, uniqueIntermezzo, University, upfront, usedIntermezzo, useIntermezzo, view, visual, washout, withinIntermezzo, withIntermezzo, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PRTK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Transcept Pharmaceuticals, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the annual period ended December 31, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 30, 2012

/s/ Glenn A. Oclassen

Glenn A. Oclassen

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Thomas P. Soloway

Thomas P. Soloway

Senior Vice President, Operations and

Chief Financial Officer

(Principal Financial Officer)

A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.